Published: January 7, 2026 at 8:42 am
A listed University of Leeds spinout in danger of going insolvent has left the London Stock Exchange after two decades.
In December Tissue Regenix Group secured $500,000 in emergency funding to help it to remain afloat, having appointed a new leadership team in October following the discovery of errors in previously reported revenues.
Trading in its shares on London’s AIM market have been suspended since that time as it restated its 2024 revenue figures.
Following approval at a shareholder meeting just before Christmas, the regenerative medical devices company has today cancelled the admission to trading on AIM of its ordinary shares.
The company has appointed a secondary market trading facility, Asset Match, to facilitate trading in its shares. Asset Match, a firm authorised and regulated by the Financial Conduct Authority, will operate an electronic off-market dealing facility for these.